Ingebrigtsen Tor, Romner Bertil
Department of Neurosurgery, University Hospital of North Norway, N-9038 Tromsø, Norway.
Restor Neurol Neurosci. 2003;21(3-4):171-6.
To provide an overview of clinical research on the use of biochemical serum markers for traumatic brain injury (TBI) in the evaluation of patients with mild head injuries (MHI).
The MEDLINE database was searched for publications on biochemical serum markers of TBI until August 2002. Clinical studies addressing their use in MHI were reviewed.
Desirable characteristics for biochemical serum markers of TBI were identified. Creatine kinase isoenzyme BB (CK-BB), neuron specific enolase (NSE) and S-100B protein have been most extensively studied. The sensitivity and specificity of CK-BB is inadequate for use as an indicator of traumatic brain injury. Serum levels of NSE do not correspond to the amount of TBI, probably because of its long (20 h) half-life. S-100B serum levels are correlated to both clinical measures of injury severity, neuroradiological findings and outcomes in several studies from different authors.
Currently, S-100B protein is the most promising marker for evaluation of TBI in patients with MHI.
概述使用生化血清标志物评估轻度颅脑损伤（MHI）患者创伤性脑损伤（TBI）的临床研究。
检索MEDLINE数据库中截至2002年8月有关TBI生化血清标志物的出版物。对涉及它们在MHI中应用的临床研究进行综述。
确定了TBI生化血清标志物的理想特征。肌酸激酶同工酶BB（CK-BB）、神经元特异性烯醇化酶（NSE）和S-100B蛋白研究最为广泛。CK-BB用作创伤性脑损伤指标的敏感性和特异性不足。NSE血清水平与TBI的严重程度不对应，可能是因为其半衰期长（20小时）。在不同作者的多项研究中，S-100B血清水平与损伤严重程度的临床指标、神经放射学检查结果及预后均相关。
目前，S-100B蛋白是评估MHI患者TBI最有前景的标志物。
